Clinical Trials
35 trialsNCT02135419 2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3 Completed
NCT04895020 2024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Unknown
NCT05027776 2024-04-17
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05372016 2023-11-24
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT05580341 2022-10-28
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Unknown
NCT00943722 2022-10-03
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01164722 2020-08-04
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
AIDS Malignancy Consortium
Phase 3 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's GardasilĀ® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01190176 2019-10-30
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00937950 2019-10-29
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00779766 2019-06-10
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01254643 2018-11-28
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00543543 2018-11-27
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01245764 2018-11-14
GARDASILā¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02346227 2018-10-12
KINVAV
Universiteit Antwerpen
Phase 3 Completed
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00652938 2018-08-17
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00345878 2018-07-20
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
GlaxoSmithKline
Phase 3 Completed
NCT00485732 2018-07-20
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
GlaxoSmithKline
Phase 3 Completed
NCT00799825 2018-07-12
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
GlaxoSmithKline
Phase 3 Completed
NCT00552279 2018-06-25
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00973362 2017-01-06
Clinical Evaluation of the APTIMAĀ® HPV Assay Using the TIGRISĀ® System
Gen-Probe, Incorporated
Phase 3 Completed
NCT00306241 2016-11-04
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
GlaxoSmithKline
Phase 3 Completed
NCT00929526 2016-10-20
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
GlaxoSmithKline
Phase 3 Completed
NCT00849381 2014-09-12
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
GlaxoSmithKline
Phase 3 Completed
NCT00316706 2012-09-18
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
GlaxoSmithKline
Phase 3 Completed